[go: up one dir, main page]

IN2014CN02114A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02114A
IN2014CN02114A IN2114CHN2014A IN2014CN02114A IN 2014CN02114 A IN2014CN02114 A IN 2014CN02114A IN 2114CHN2014 A IN2114CHN2014 A IN 2114CHN2014A IN 2014CN02114 A IN2014CN02114 A IN 2014CN02114A
Authority
IN
India
Prior art keywords
hemagglutinin polypeptides
glycosylation sites
same
flu hemagglutinin
flu
Prior art date
Application number
Other languages
English (en)
Inventor
Sastre Adolfo Garcia
Peter Palese
Florian Krammer
Natalie Pica
Dirk Eggink
Silva Rafael A Medina
Rong Hai
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of IN2014CN02114A publication Critical patent/IN2014CN02114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2114CHN2014 2011-09-20 2012-09-19 IN2014CN02114A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161536924P 2011-09-20 2011-09-20
US201161565899P 2011-12-01 2011-12-01
US201261607526P 2012-03-06 2012-03-06
US201261648525P 2012-05-17 2012-05-17
US201261670108P 2012-07-10 2012-07-10
US201261684481P 2012-08-17 2012-08-17
PCT/US2012/056122 WO2013043729A1 (fr) 2011-09-20 2012-09-19 Vaccins contre le virus de la grippe et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2014CN02114A true IN2014CN02114A (fr) 2015-05-29

Family

ID=47914828

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2114CHN2014 IN2014CN02114A (fr) 2011-09-20 2012-09-19

Country Status (17)

Country Link
US (2) US10131695B2 (fr)
EP (2) EP4241785A3 (fr)
JP (4) JP6498439B2 (fr)
KR (1) KR20140068205A (fr)
CN (3) CN116162175A (fr)
AR (1) AR090392A1 (fr)
AU (2) AU2012312529B2 (fr)
BR (1) BR112014006694A2 (fr)
CA (1) CA2849434A1 (fr)
EA (1) EA201490659A1 (fr)
ES (1) ES2953393T3 (fr)
HK (1) HK1200102A1 (fr)
IL (2) IL231547B (fr)
IN (1) IN2014CN02114A (fr)
MX (1) MX2014003308A (fr)
SG (1) SG11201400743VA (fr)
WO (1) WO2013043729A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP2934581B1 (fr) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN113667013B (zh) * 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
SG10201912038TA (en) * 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
CA2986096A1 (fr) * 2014-05-30 2015-12-03 Sanofi Pasteur Inc. Expression et analyse de conformation de l'hemagglutinine de la grippe genetiquement modifiee
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
CA2954780A1 (fr) 2014-07-15 2016-01-21 Medimmune, Llc Neutralisation d'anticorps anti-grippe b et leurs utilisations
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
MX2017014146A (es) 2015-05-04 2018-08-14 Epivax Inc Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
WO2016205347A1 (fr) * 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
CN109073639B (zh) * 2016-02-03 2022-04-01 Cg探索股份有限公司 具有异源表位和/或改变的成熟切割位点的流感血凝素的组合物
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
JP6868763B2 (ja) * 2016-04-01 2021-05-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
CA3026094A1 (fr) * 2016-06-03 2017-12-07 Sanofi Pasteur Inc. Polypeptides d'hemagglutinine d'influenza modifies
EP3463447A4 (fr) * 2016-06-03 2020-05-27 Icahn School of Medicine at Mount Sinai Régimes de vaccination contre le virus de la grippe
EP3471767A4 (fr) * 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Hémagglutinines du virus de la grippe et utilisations de celles-ci
EP3506938A1 (fr) 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Trimères à région tige stabilisée de l'hémagglutinine du virus de la grippe du groupe 2 et leurs utilisations
WO2018085488A1 (fr) 2016-11-02 2018-05-11 Iowa State University Research Foundation, Inc. Vaccin universel contre la grippe chez les mammifères
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018175560A1 (fr) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticules immunogènes aptes à provoquer des réponses contre le site de liaison au récepteur de la grippe sur le domaine tête de l'hémagglutinine
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
MX2020010199A (es) * 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
US12304928B2 (en) 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
EP3810634A4 (fr) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Polypeptides d'hémagglutinines du virus de la grippe en mosaïque et leurs utilisations
US20210225457A1 (en) * 2018-07-13 2021-07-22 University Of Georgia Research Foundation Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN109096376A (zh) * 2018-09-20 2018-12-28 扬州大学 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法
KR102098585B1 (ko) * 2018-11-21 2020-04-08 고려대학교 산학협력단 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신
CN115605491A (zh) 2019-04-05 2023-01-13 刘扶东（Us） 抗唾液酸酶的糖类、其制造方法及用途
KR20220036909A (ko) * 2019-04-06 2022-03-23 알티뮨 인크. 광범위하고 오래 지속되는 인플루엔자 백신
TWI817041B (zh) * 2019-09-20 2023-10-01 中央研究院 嵌合血球凝集素蛋白質及包含其之疫苗組成物
CA3158145A1 (fr) * 2019-10-15 2021-04-22 Janssen Vaccines & Prevention B.V. Vaccins contre le virus de la grippe et leurs utilisations
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
CN116075315B (zh) 2020-05-08 2025-12-19 周美吟 嵌合流感疫苗
CN112111503B (zh) * 2020-08-24 2023-04-07 河北省动物疫病预防控制中心 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法
WO2022155649A1 (fr) * 2021-01-12 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccin contre la grippe dérivé du virus herpès simplex de type 1
CN113082187B (zh) * 2021-04-09 2023-06-27 北京红太阳药业有限公司 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用
US12257298B2 (en) 2021-04-12 2025-03-25 Academia Sinica Coronavirus vaccine
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CA3268566A1 (fr) 2023-04-08 2024-10-17 Rock Biomedical Inc. Procédés et compositions pour une distribution ciblée par des polymersomes
WO2025092866A1 (fr) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 Vaccin à arnm antigrippe multivalent

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0621339B1 (fr) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Polypeptides immunogès dérivées du haemagglutinen de virus de la influenza type A humain
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994012629A1 (fr) 1992-12-02 1994-06-09 Baylor College Of Medicine Vecteurs episomiques pour therapie genique
WO1994016109A1 (fr) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Evenements de fusion de membrane et leur moyen de modification
WO1994017826A1 (fr) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccins polypeptidiques
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
WO1996011279A2 (fr) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Reponse immunitaire amelioree par l'introduction par recombinaison du gene de la cytokine et/ou du gene de la proteine co-stimulatrice b7 dans un systeme d'expression virale
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
ATE426031T1 (de) 1995-09-14 2009-04-15 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
CA2230033C (fr) 1995-09-27 2010-01-26 Peter L. Collins Production de virus syncytial respiratoire infectieux a partir de sequences de nucleotides clones
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
CA2252438C (fr) 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Intimine marquee a l'histidine et procedes d'utilisation de l'intimine pour stimuler une reaction immunitaire et en tant que porteur d'antigene a capacite de ciblage
DE69736226T2 (de) 1996-04-19 2006-11-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
EP0932684A2 (fr) 1996-09-27 1999-08-04 American Cyanamid Company Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
DE69800716T2 (de) 1997-04-14 2001-09-20 Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
JP4434478B2 (ja) 1997-07-11 2010-03-17 イエール ユニバーシティー リエンジニアリングされた外被を有するラブドウイルス
CA2302867A1 (fr) 1997-09-19 1999-04-01 American Cyanamid Company Virus syncytiaux respiratoires attenues
PT1085904E (pt) 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
US6468544B1 (en) 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AU776855B2 (en) 1998-12-23 2004-09-23 Boyce Thompson Institute For Plant Research Inc. Expression of immunogenic hepatitis B surface antigens in transgenic plants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ES2262514T3 (es) 1999-04-29 2006-12-01 Syngenta Limited Plantas resistentes a herbicidas.
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
MXPA02003069A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Vacuna intranasal contra el virus de la influenza..
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
US6951754B2 (en) 2000-04-28 2005-10-04 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
ES2563402T3 (es) 2002-02-13 2016-03-15 Wisconsin Alumni Research Foundation Señal para el empaquetamiento de vectores del virus de la gripe
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP4892705B2 (ja) * 2002-08-20 2012-03-07 オプサニテクス エルエルシー レクチン組成物および抗原に対する免疫反応を調節するための方法
WO2004067553A2 (fr) 2003-01-29 2004-08-12 The Research Foundation Of The State University Of New York Production d'anticorps cibles induits par la tolerance
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
WO2004098533A2 (fr) 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vecteurs et cellules utilises dans la preparation de compositions immunoprotectrices issues de vegetaux transgeniques
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
PL2261377T3 (pl) 2003-11-04 2014-03-31 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
AU2005248375B2 (en) 2004-05-25 2010-12-16 Medimmune, Llc Influenza hemagglutinin and neuraminidase varians
MX2007004414A (es) 2004-10-13 2007-09-25 Protalix Ltd Sistema y metodo para la produccion de anticuerpos en cultivos de celulas de plantas.
JP2008519042A (ja) * 2004-11-03 2008-06-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インフルエンザワクチン接種
EP1851238A4 (fr) 2005-02-24 2008-12-31 Univ Massachusetts Acides nucleiques d'influenza, polypeptides et leurs utilisations
WO2006130855A2 (fr) 2005-06-01 2006-12-07 California Institute Of Technology Procede permettant le transfert cible de genes au moyen de vecteurs viraux
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
KR20070000554A (ko) 2005-06-27 2007-01-03 삼성전자주식회사 이종 망에서 복합 서비스를 위한 자원 관리방법
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
TWI531652B (zh) * 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
ATE552846T1 (de) 2005-12-06 2012-04-15 Yeda Res & Dev Verbesserter grippeimpfstoff
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007109812A2 (fr) 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
EP2023952B1 (fr) 2006-05-18 2015-07-15 Epimmune Inc. Induction de réponses immunitaires au virus de la grippe en utilisant des compositions de polypeptides et d'acides nucléiques
WO2008002238A1 (fr) 2006-06-27 2008-01-03 Addbio Ab Dispositif de délivrance de médicament, kit et procédé de traitement pharmacologique local peropératoire de surfaces osseuses
EP2035565A4 (fr) 2006-06-30 2010-07-21 Novavax Inc Procédés d'amélioration de l'incorporation de protéines dans des particules de type virus (vlp)
ES2428067T3 (es) 2006-07-21 2013-11-05 California Institute Of Technology Introducción selectiva de genes para la vacunación con células dendríticas
EP2059532B1 (fr) 2006-09-07 2012-12-26 Crucell Holland B.V. Molécules de liaison humaines capables de neutraliser le virus de la grippe h5n1 et leurs utilisations
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
EP2174957B1 (fr) 2007-06-15 2016-03-16 Xiamen University Anticorps monoclonaux se liant a l'hemagglutinine du virus de la grippe aviaire du sous type h5 et ses utilisations
EP2014279A1 (fr) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes contenant de l'hémagglutinine dérivée du virus de la grippe produit par les lignées cellulaires; les compositions, les méthodes de production, l'emploi des virosomes
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
CA2615372A1 (fr) 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
CA2693899A1 (fr) 2007-07-19 2009-01-22 Novavax, Inc. Pseudo-particules virales du virus chimere de la varicelle et du zona
WO2009025770A2 (fr) 2007-08-17 2009-02-26 Wyeth Thérapie d'immunisation hétérologue de type sensibilisation-rappel
WO2009088401A2 (fr) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Combinaisons immunostimulantes de ligands tlr et leurs procédés d'utilisation
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2238253B1 (fr) 2007-11-27 2012-09-12 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
WO2009092038A1 (fr) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccination a base d'adn de la grippe et methodes d'utilisation associees
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2540740B1 (fr) 2008-06-17 2014-09-10 Apogenix GmbH Récepteurs multimériques TNF
EP2695941B1 (fr) 2008-06-25 2015-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveaux composés immunoadjuvants à base de flagelline et leur utilisation
CA2730171C (fr) * 2008-07-08 2016-10-11 Medicago Inc. Antigenes de la grippe recombines solubles
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
NZ597401A (en) 2009-06-24 2013-09-27 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
CA2805505C (fr) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Virus de l'influenza chimeriques ayant une capacite reduite a s'associer a d'autres virus de l'influenza et utilisations desdits virus
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
MX338758B (es) * 2010-03-08 2016-04-29 Celltrion Inc Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
ES2739711T3 (es) 2010-07-22 2020-02-03 John W Schrader Anticuerpo de protección cruzada contra la infección por el virus de la gripe
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
WO2014090865A1 (fr) 2012-12-11 2014-06-19 Vib Vzw Anticorps anti-grippe
EP2934581B1 (fr) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
HK1214962A1 (zh) 2013-01-10 2016-08-12 Seqirus UK Limited 流感病毒免疫原性组合物及其应用
BR112015021880A2 (pt) 2013-03-13 2017-09-26 Novartis Ag rearranjo de vírus influenza b
WO2014152841A1 (fr) 2013-03-14 2014-09-25 Contrafect Corporation Composition et méthodes fondées sur des anticorps neutralisants administrés par voie intranasale pour une efficacité thérapeutique améliorée
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR20150127586A (ko) 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 핵산 분자 및 이로부터 제조된 백신
PL235555B1 (pl) 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016205347A1 (fr) 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
EP3463447A4 (fr) 2016-06-03 2020-05-27 Icahn School of Medicine at Mount Sinai Régimes de vaccination contre le virus de la grippe
EP3471767A4 (fr) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Hémagglutinines du virus de la grippe et utilisations de celles-ci

Also Published As

Publication number Publication date
JP2018110585A (ja) 2018-07-19
AU2012312529A1 (en) 2014-03-27
KR20140068205A (ko) 2014-06-05
CA2849434A1 (fr) 2013-03-28
US20150132330A1 (en) 2015-05-14
SG11201400743VA (en) 2014-04-28
HK1200102A1 (en) 2015-07-31
JP2020096604A (ja) 2020-06-25
EP2758075A4 (fr) 2015-05-20
JP2014530003A (ja) 2014-11-17
CN108164602A (zh) 2018-06-15
AU2012312529B2 (en) 2018-01-04
IL262123A (en) 2018-11-29
US10131695B2 (en) 2018-11-20
IL231547A0 (en) 2014-04-30
EP4241785A2 (fr) 2023-09-13
JP6498439B2 (ja) 2019-04-17
EP2758075B1 (fr) 2023-05-03
EA201490659A1 (ru) 2014-11-28
MX2014003308A (es) 2015-03-09
CN104185476A (zh) 2014-12-03
AU2018202388A1 (en) 2018-04-26
AR090392A1 (es) 2014-11-12
BR112014006694A2 (pt) 2020-11-17
WO2013043729A1 (fr) 2013-03-28
IL231547B (en) 2018-10-31
CN116162175A (zh) 2023-05-26
JP2022091775A (ja) 2022-06-21
EP2758075A1 (fr) 2014-07-30
US20190106461A1 (en) 2019-04-11
ES2953393T3 (es) 2023-11-10
EP4241785A3 (fr) 2023-09-27

Similar Documents

Publication Publication Date Title
IN2014CN02114A (fr)
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
ZA201404797B (en) Influenza virus vaccines and uses thereof
EP2552479A4 (fr) Vaccins contre le virus de la grippe et utilisations associées
ZA201200481B (en) Chimeric influenza virus-like particles comprising hemagglutinin
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
GB201115214D0 (en) Influenza virus antibody compositions
ZA201509229B (en) Influenza virus vaccines and uses thereof
IL229307A0 (en) Inactivated dengue virus vaccine
IL240936B (en) Reassortment of influenza virus and methods for their preparation
SG11201507460PA (en) Compositions and methods for dengue virus chimeric constructs in vaccines
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
IL227947A0 (en) Preparations containing antibodies that bind to the glycoprotein hemagglutinin a and the extracellular domain of the polypeptide to the transverse domain of matrix 2 (e2m) from influenza virus origin and their uses
PL2969005T3 (pl) Atenuowane wirusy grypy i szczepionki
EP3212672A4 (fr) Procédés et compositions permettant l'obtention de virus de la dengue recombinés pour le développement de vaccins et d'outils de diagnostic
EP2650362A4 (fr) Nouveaux vaccins contre le virus de la grippe pandémique a/h1n1
EP3013852A4 (fr) Procédés et compositions pour des vaccins contre le virus de la dengue
EP2632941A4 (fr) Protéine d'hémagglutinine recombinante du virus de la grippe et vaccin la contenant
BR112014002290A2 (pt) vírus recombinante de influenza suína e usos do mesmo
HK1180225A (en) Influenza virus vaccines and uses thereof
HK1192850A (en) Inactivated dengue virus vaccine